Brief: Renovorx Presenting Phase Iii Trial Interim Analysis Data At American Association For Cancer Research Annual Meeting In Florida
14/04/2023 14:56
April 14 (Reuters) - RenovoRx Inc RNXT.O :
* RENOVORX PRESENTING PHASE III CLINICAL TRIAL INTERIM
ANALYSIS
DATA OF THE TIGER-PAC STUDY AT AMERICAN ASSOCIATION FOR CANCER
RESEARCH ANNUAL MEETING UNDERWAY IN ORLANDO, FLORIDA
Source text for Eikon: ID:nBw5X8rt7a
Further company coverage: RNXT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on RenovoRx
See all newsBrief: Renovorx Advances Tamp Into Borderline Resectable Pancreatic Cancer With First Patient Enrolled In Investigator-Initiated Prism-Tamp Trial
RenovoRx Inc reports results for the quarter ended June 30 - Earnings Summary
Oncology device maker RenovoRx's Q2 revenue surges, raises FY outlook
Brief: RenovoRx Q2 Net Income USD -2.911 Million
Brief: Renovorx Achieves Major Milestone With Full Enrollment In Phase Iii Tiger-Pac Trial For Locally Advanced Pancreatic Cancer